| ABSTRACT Objective:The purpose of this Meta analysis was to evaluate the efficacy of Alirocumab (an anti PCSK9 antibody) for treating dyslipidemia. Methods:Pubmed, Embase, the Cochrane Library, Clinical Trials.gov databases, CNKI, VIP database and recent conferences were searched for phase 2 and 3 randomized controlled trials (RCTs) comparing Alirocumab with placebo or ezetimibe for dyslipidemia. Meta analysis of the data were extracted and analyzed using the Software RevMan 5.3.Results:Included 18 RCTs with a total of 6 748 patients, 13 RCTs were compared Alirocumab (n=3606) with ezetimibe (n=1658) and 5 RCTs were compared Alirocumab (n=864) with placebo (n=620). LDL C in Alirocumab group was significantly decreased than those in ezetimibe group [MD=-30.50%, 95%CI: (-33.68%, -27.33%)], and than those in placebo group [MD=-52.25%, 95%CI: (-55.85%, -48.65%)]. LDL C in Alirocumab group was significantly decreased than those in ezetimibe group [MD=-30.30%, 95%CI: (-34.43% , -26.17%)], and than those in placebo group [MD=-50.64% , 95%CI: (-54.95% to -46.33%)] though patients were on stable statin treatment. And also significant and favorable changes were also detected in other lipids of Alirocumab group. Alirocumab substantially reduced the level of Apo B, Non HDL C, Lp(a), TGs and TC, increased the HDL C and Apo A 1 level.Conclusion:The PCSK9 inhibitor Alirocumab could be an add on therapy to lipid lowering drugs for patients who had established dyslipidemia or high cardiovascular (CV) risk with LDL C inadequately controlled on stable statin treatment or statin intolerance. |
